Varenicline for Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial

Alcoholism: Clinical and Experimental Research

Volumn 39, Issue 11, 2015, Pages 2189-2199

  de Bejczy, Andrea ^a,b   Löf, Elin ^a,b   Walther, Lisa ^c   Guterstam, Joar ^d   Hammarberg, Anders ^d   Asanovska, Gulber ^e   Franck, Johan ^d   Isaksson, Anders ^c   Söderpalm, Bo ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alcohol Dependence; Alcohol Markers; Nicotinergic Acetylcholine Receptors; PEth; Phospha tidylethanol; Varenicline

Indexed keywords

ALCOHOL; CARBOHYDRATE DEFICIENT TRANSFERRIN; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; VARENICLINE; NICOTINIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ADVERTIZING; AGED; ALCOHOL CONSUMPTION; ALCOHOL USE DISORDERS IDENTIFICATION TEST; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTHRALGIA; ARTICLE; ASSESSMENT OF HUMANS; BACKACHE; CAUCASIAN; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DSM-IV; FAMILY HISTORY; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INNER EAR DISEASE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SLEEP DISORDER; SWEDEN; UNIVERSITY HOSPITAL; VERTIGO; XEROSTOMIA; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; AGED; ALCOHOLISM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; SINGLE-BLIND METHOD; SWEDEN; TREATMENT OUTCOME; VARENICLINE;

EID: 84945298783     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12854     Document Type: Article

References (36)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text rev. American Psychiatric Association, Washington, DC.
2. Anton RF, Moak DH, Latham P (1995) The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1:92-99.
3. Balfour DJ (2009) The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol 192:209-233.
4. Berman AH, Bergman H, Palmstierna T, Schlyter F (2003) DUDIT, the Drug Use Disorders Identification Test. Karolinska Institutet, Stockholm, Sweden.
5. Blomqvist O, Engel JA, Nissbrandt H, Soderpalm B (1993) The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. Eur J Pharmacol 2:207-213.
6. Cuijpers P, Smit F (2001) Assessing parental alcoholism: a comparison of the family history research diagnostic criteria versus a single-question method. Addict Behav 5:741-748.
7. Ericson M, Lof E, Stomberg R, Soderpalm B (2009) The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther 1:225-230.
8. Fagerstrom KO (1991) Towards better diagnoses and more individual treatment of tobacco dependence. Br J Addict 5:543-547.
9. Forsberg L, Ekman S, Halldin J, Ronnberg S (2004) The readiness to change questionnaire: reliability and validity of a Swedish version and a comparison of scoring methods. Br J Health Psychol 3:335-346.
10. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS (2011) A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology 4:655-663.
11. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, for the Varenicline Phase 3 Study G (2006) Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 1:47-55.
12. Gual A, He Y, Torup L, van den Brink W, Mann K (2013) A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 23:1432-1442.
13. Helander A, Husa A, Jeppsson JO (2003) Improved HPLC method for carbohydrate-deficient transferrin in serum. Clin Chem 49:1881-1890.
14. Hughes JC, Cook CC (1997) The efficacy of disulfiram: a review of outcome studies. Addiction 4:381-395.
15. Isaksson A, Walther L, Hansson T, Andersson A, Alling C (2011) Phosphatidylethanol in blood (B-PEth): a marker for alcohol use and abuse. Drug Test Anal 3:195-200.
16. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 9370:1677-1685.
17. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 8:963-971.
18. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 1:56-63.
19. Katner SN, Weiss F (2001) Neurochemical characteristics associated with ethanol preference in selected alcohol-preferring and -nonpreferring rats: a quantitative microdialysis study. Alcohol Clin Exp Res 2:198-205.
20. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, Ustun TB, Walters EE (2005) The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2:245-256.
21. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 9:1335-1341.
22. Larsson A, Jerlhag E, Svensson L, Söderpalm B, Engel JA (2004) Is an alpha-conotoxin MII-sensitive mechanism involved in the neurochemical, stimulatory, and rewarding effects of ethanol. Alcohol 34:239-250.
23. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R, NCIG (National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group) Study Group (2013) A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 7:277-286.
24. Mann K, Bladstrom A, Torup L, Gual A, van den Brink W (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 8:706-713.
25. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E (2009) Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 2:185-190.
26. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL (2012) Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology 223:299-306.
27. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
28. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD III, Williams KE (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 3:985-994.
29. Saunders JB, Aasland OG, Amundsen A, Grant M (1993) Alcohol consumption and related problems among primary health care patients: WHO collaborative project on early detection of persons with harmful alcohol consumption-I. Addiction 3:349-362.
30. Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H (2014) Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology 231:3799-3807.
31. Soderpalm B, Ericson M, Olausson P, Blomqvist O, Engel JA (2000) Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res 1-2:85-96.
32. Spitzer RL, Williams JBW, Gibbon M, First MB (1990) Structured Clinical Interview for DSM-III-R, Patient Edition/Non-Patient Edition, (SCID-P/SCID-NP). American Psychiatric Press Inc, Washington, DC.
33. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 30:12518-12523.
34. Tizabi Y, Bai L, Copeland RL Jr, Taylor RE (2007) Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol 5:413-416.
35. Walther L, de Bejczy A, Löf E, Hansson T, Andersson A, Guterstam J, Hammarberg A, Asanovska G, Franck J, Söderpalm B, Isaksson A (2015) Phosphatidylethanol is superior to carbohydrate-deficient transferrin and γ-glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption level. Alcohol Clin Exp Res. doi: 10.1111/acer.12883.
36. Wynn PA (2000) The reliability of personal alcohol consumption estimates in a working population. Occup Med (Lond) 5:322-325.